3115eP Real-world clinical outcomes of avelumab (A), pembrolizumab (P) or enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC) with squamous differentiation (UCSD): Results from the Aron-2 study | Publicación